<DOC>
	<DOCNO>NCT01717586</DOCNO>
	<brief_summary>The primary purpose pilot study determine pharmacokinetic ( PK ) parameter collect preliminary safety data pravastatin use prophylactic daily treatment pregnant woman high risk preeclampsia .</brief_summary>
	<brief_title>Pravastatin Prevention Preeclampsia</brief_title>
	<detailed_description>Preeclampsia share pathogenic similarity adult cardiovascular disease well many risk factor . Endothelial dysfunction inflammation fundamental initiation progression . There strong evidence 3-hydroxy-3-methylglutaryl-coenzyme A ( HMG-CoA ) reductase inhibitor ( statin ) beneficial primary secondary prevention cardiovascular mortality cardiovascular event . Biological plausibility well animal data support similar role statin preeclampsia . Currently , clinically available agent prevent preeclampsia . However property statin , class medication could substantially contribute preeclampsia prevention . 1 . Statins pleiotropic action various mechanism : reverse angiogenic imbalance upregulating vascular endothelial growth factor ( VEGF ) placental growth factor ( PlGF ) , reduce antiangiogenic factor soluble fms-like tyrosine kinase-1 ( sFlt-1 ) soluble endoglin ( sEng ) . 2 . Statins regulation endothelial nitric oxide synthase , lead improve nitric oxide production vasculature activate heme oxygenase-1/carbon monoxide ( HO-1/CO ) pathway , protect endothelium reduce inflammatory oxidative insult . The purpose pilot study evaluate maternal-fetal safety pharmacokinetic ( PK ) profile pravastatin use pregnant woman high-risk develop preeclampsia .</detailed_description>
	<mesh_term>Pre-Eclampsia</mesh_term>
	<mesh_term>Pravastatin</mesh_term>
	<criteria>Documented history ( chart review ) prior severe preeclampsia either two pregnancy precede current one requiring delivery 34 complete week less gestation . 18 year old ability give inform consent Singleton pregnancy Normal serum transaminase ( ALT AST ) concentration last 6months Gestational age ( GA ) 12 week 0 day 16 week 6 day base clinical information confirm ultrasound per study procedure Known chromosomal , genetic , major fetal malformation , fetal demise , plan termination Multifetal gestation Patients contraindication statin therapy : Hypersensitivity pravastatin component product Active liver disease past 6 month ( acute hepatitis , chronic active hepatitis , persistently abnormal liver enzyme ( 2 x normal serum transaminase ) History myopathy rhabdomyolysis Patients follow condition : HIV positive Status post solid organ transplant Chronic renal disease/insufficiency baseline serum creatinine ≥1.5 mg/dL Uterine malformation Cancer Statin use current pregnancy last month prior pregnancy Concurrent chronic ( &gt; 6 month ) use medication potential drug interaction statin , immunosuppressive drug , fibrates , gemfibrozil , niacin , erythromycin , clarithromycin , itraconazole , cholestyramine , digoxin , rifampin ( patient exclude drug discontinue , prescribe short duration time ) Participating another intervention study influence outcomes study Plans deliver nonnetwork site</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>preeclampsia</keyword>
	<keyword>pravastatin</keyword>
	<keyword>Pravachol®</keyword>
	<keyword>statin</keyword>
	<keyword>high-risk pregnancy</keyword>
	<keyword>safety</keyword>
	<keyword>fetal morbidity mortality</keyword>
	<keyword>maternal morbidity mortality</keyword>
	<keyword>neonatal mortality</keyword>
	<keyword>premature delivery</keyword>
	<keyword>preemie</keyword>
</DOC>